BioAtla Investor Presentation Deck

Key milestones and catalysts throughout 2024 1H BA3071: o Evaluate safety and efficacy of BA3071 at 10mg/kg and potentially, 14.2mg/kg dose levels o Initial readout Phase 2 in treatment-refractory solid tumors (~20 pts) o Demonstrate supportive data as mono- and combo- therapy BA3011: o Confirm clinical benefit in target-agnostic NSCLC patients (~30 pts) o Update UPS status bicatla 2024 BA3021: Readout final data sets in melanoma (n = ~25 pts) and SCCHN (~20 pts) BA3071: 2H Readout additional Phase 2 data in treatment-refractory solid tumors O Define pivotal path for BA3071 in treatment-refractory indications Initiate potentially registrational study with either BA3071 in a solid tumor and/or BA3011 in NSCLC Establish strategic collaboration for BA3071 and/or one CAB ADC EpCAM Phase 1 data readout; initiate Phase 2 as data support BioAtla| Overview 54

View entire presentation